Novartis To Resubmit Galvus In Mid-2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety study responding to FDA’s “approvable” letter for the type 2 diabetes therapy will take months, not weeks; firm also faces delay for oncologic Tasigna.
You may also be interested in...
Galvus Won’t Proceed In U.S. Without More FDA Clarity On Prospects, Novartis Says
DPP-4 inhibitor’s NDA is on hold in U.S. while firm pursues European launch; Novartis balks at FDA request for large safety study.
Galvus Won’t Proceed In U.S. Without More FDA Clarity On Prospects, Novartis Says
DPP-4 inhibitor’s NDA is on hold in U.S. while firm pursues European launch; Novartis balks at FDA request for large safety study.
Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market
NDA for alogliptin submitted Dec. 27, Takeda tells “The Pink Sheet” DAILY, giving the drug an expected Oct. 27, 2008, PDUFA date with standard review.